Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Clinical trial NCT06224049 · UNKNOWN
Trial details
- NCT number
- NCT06224049
- Sponsor
- BGI, China
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-01
- Primary completion
- 2025-06-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.